BioClin Therapeutics Presents FIERCE-21: Phase 1b/2 Study of Docetaxel + B-701, a Selective Inhibitor of FGFR3, in Relapsed or Refractory Metastatic Urothelial Carcinoma at the American Society of Clinical Oncology (ASCO). Chicago, IL.

June 1, 2018

Source: Biocline Therapeutics

Stockholm office

Engelbrektsplan 1
114 34 Stockholm
Sweden

+46 8 442 58 50

Lausanne office

Avenue Villamont 23
CH – 1005 Lausanne
Switzerland

+41 21 614 35 00

Legal

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies

Please enable Strictly Necessary Cookies first so that we can save your preferences!